期刊文献+

阿戈美拉汀与度洛西汀治疗抑郁症患者的疗效分析 被引量:13

Efficacy analysis of Agomelatine versus Duloxetine on depressive disorder
下载PDF
导出
摘要 目的:探讨阿戈美拉汀与度洛西汀治疗抑郁症患者的疗效分析。方法:对符合ICD-10诊断的108例抑郁症患者按随机数字表法分为研究组和对照组,每组各54例。研究组患者单一使用阿戈美拉汀治疗;对照组患者单一使用度洛西汀治疗。在基线、2周末、4周末、8周末,采用汉密顿抑郁量表(HAMD)和不良反应症状量表(TESS)对两组患者进行疗效和安全性评估。结果:在治疗后8周末,研究组和对照组患者的临床治疗有效率分别为72.2%和63.0%,两组患者比较,差异无统计学意义(P>0.05)。治疗后第2、4、8周末,两组患者的HAMD总分与治疗前比较均显著下降(P<0.01),两组间比较差异无统计学意义(P>0.05)。研究组患者的不良反应与对照组比较,得分及分布差异均无统计学意义(P>0.05)。结论:阿戈美拉汀治疗抑郁症患者的疗效与度洛西汀相当。 Objective To evaluate efficacy of Agomelatine versus Duloxetine on depressive disorder. Methods: 108 patients meeting 1CD-10 criteria of depressive disorders were randomized into study group (n = 54, treated with Agomelatine for 8 weeks) and control group (n = 54, treated with Duloxetine for 8 weeks). All patients were assessed with Hamilton depression scale (HAMD) and treatment emergent symptom scale (TESS) at baseline and the end of the 2nd, 4th, 8th week of the treatment to evaluate the efficacy and safety, respectively. Results: There was no significant difference in response rate at the end of the 8th week between study group and control group (72.2% vs 63.0%%, P〉0. 05). The scores of HAMD in both group decreased significantly at the end of the 2nd, 4th, and 8th week when compared with the baseline ( P〈0. 01) , but there was also no significant difference between the two groups ( P 〉0.05). There were no significant differences in frequency and score of side effects between study group and control group ( P 〉 0.05). Conclusions: Compared with Duloxetine, Agomelatine has similar therapeutic effects in the treatment of patients with depres-sive disorders.
出处 《中国民康医学》 2016年第12期4-6,9,共4页 Medical Journal of Chinese People’s Health
关键词 阿戈美拉汀 度洛西汀 抑郁症 Agomelatine Duloxetine Depressive disorderC
  • 相关文献

参考文献7

二级参考文献102

  • 1石其昌,章健民,徐方忠,费立鹏,许毅,傅永利,顾卫,周夏江,王淑敏,张滢,俞敏.浙江省15岁及以上人群精神疾病流行病学调查[J].中华预防医学杂志,2005,39(4):229-236. 被引量:299
  • 2Sartorius N,Baghai TC,Baldwin DS,et al.Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence[J]. Int J Neuropsychopharmacol,2007,10 (Suppl.1): S1-207.
  • 3Millan MJ.Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates,drug discovery and therapeutic application[J]. Pharmacol THer,2006,110(2): 135-370.
  • 4Souêtre E,Salvati E,Belugou JL,et al.Circadian rhythms in depression and recovery: evidence for blunted amplitude as the main chronobiological abnormality[J]. Psychiatry Res,1989,28(3): 263-278.
  • 5Duncan WC Jr.Circadian rhythms and the pharmacology of affective illness[J]. Pharmacol Ther,1996,71(3): 253-312.
  • 6Germain A,Kupfer DJ.Circadian rhythm disturbances in depression[J]. Hum Psychopharmacol,2008,23(7): 571-585.
  • 7Audinot V,Mailliet F,Lahaye-Brasseur C,et al.New selective ligands of human cloned melatonin MT1 and MT2 receptors[J]. Naunyn Schmiedebergs Arch Pharmacol,2003,367(6): 553-561.
  • 8Kasper S,Hamon M.Beyond the monoaminergic hypothesis: agomelatine,a new antidepressant with an innovative mechanism of action[J]. World J Biol Psychiatry,2009,10(2): 117-126.
  • 9de Bodinat C,Guardiola-Lemaitre B,Moca r E,et al.Agomelatine,the first melatonergic antidepressant: discovery,characterization and development[J]. Nat Rev Drug Discov,2010,9(8): 628-642.
  • 10Yous S,Andrieux J,Howell HE,et al.Novel naphthalenic ligands with high affinity for the melatonin receptor[J]. J Med Chem,1992,35(8): 1484-1486.

共引文献247

同被引文献105

引证文献13

二级引证文献73

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部